Thrombosis Research
Volume 126, Issue 2 , Pages 144-149, August 2010

Optimizing thrombelastography (TEG) assay conditions to monitor rFVIIa (NovoSeven®) therapy in haemophilia a patients

  • Dorthe Viuff

      Affiliations

    • Medical and Science Department, Haemophilia, Novo Nordisk A/S, Søborg, Denmark
    • Corresponding Author InformationCorresponding author. Medical and Science, Haemophilia, Novo Nordisk A/S, Vandtaarnsvej 114, DK 2860 Soeborg, Denmark. Tel.: +45 44 43 16 90; fax: +45 44 42 73 90.
    • ,
  • Søren Andersen

      Affiliations

    • Biostatistics, Novo Nordisk A/S, Søborg, Denmark
    • ,
  • Brit B. Sørensen

      Affiliations

    • In vitro Haemostasis Biology, Novo Nordisk A/S, Måløv, Denmark
    • ,
  • Stefan Lethagen

      Affiliations

    • Medical and Science Department, Haemophilia, Novo Nordisk A/S, Søborg, Denmark

Received 2 March 2010; received in revised form 10 May 2010; accepted 12 May 2010. published online 10 June 2010.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

PII: S0049-3848(10)00291-4

doi:10.1016/j.thromres.2010.05.008

Thrombosis Research
Volume 126, Issue 2 , Pages 144-149, August 2010

Article Tools

* Image Usage & Resolution